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a b s t r a c t
Complexes of the type trans-[PdX2(isn)2] {X ¼ Cl (1), N3 (2), SCN (3), NCO (4); isn ¼ isonicotinamide}
were synthesized and evaluated for in vitro antimycobacterial and antitumor activities. The coordination
mode of the isonicotinamide and the pseudohalide ligands was inferred by IR spectroscopy. Single crystal
X-ray diffraction determination on 2 showed that coordination geometry around Pd(II) is nearly square
planar, with the ligands in a trans conﬁguration. All the compounds demonstrated better in vitro activity
against Mycobacterium tuberculosis than isonicotinamide and pyrazinamide. Among the complexes,
compound 2 was found to be the most active with MIC of 35.89 mM. Complexes 1e4 were also screened
for their in vitro antitumor activity towards LM3 and LP07 murine cancer cell lines.
 2010 Elsevier Masson SAS. All rights reserved.
1. Introduction
Tuberculosis (TB) is a disease of antiquity and was responsible
for about a quarter of all deaths in Europe in the middle of the 19th
century [1]. Drugs such as isoniazid (INH) and pyrazinamide (pza)
have historically been successful in the treatment of TB infections.
However, since the 1980s the disease has been undergoing
a resurgence driven by a variety of changes in social, economic and
medical factors, and with increasing urbanization in developing
countries and the increased mobility of human populations [2].
Current estimates of theWorld Health Organization (WHO) suggest
that one third of the world’s population is infected with TB bacteria
[3]. TB is now the leading infectious cause of death worldwide and
there are an estimated 9.2 million new cases of TB every year [3].
Concomitant with the resurgence of TB it has been observed the
occurrence of multi-drug resistant TB, because the treatment
involves administration of multi-drug regimen over a long period
of time, which leads to patient noncompliance [4]. For all these
reasons, there is an urgent need of new potent drugs for TB therapy.
Isonicotinamide (isn) is a pyridine derivative with an amide
group in 4-position and possesses a structural analogy with the
ﬁrst-line anti-TB drugs INH and pza (Fig. 1).
Isonicotinamide and their derivatives constitute a class of bio-
logically important compounds. For instance, some isn based-
compounds are promising reactivators for the acetylcholinesterase
inhibited by sarin [5] and paraoxon organophosphorus agent [6].
Another relevant property of isn is related to its ability to enhance
Sirt1 deacetylase activity by competing with the endogenous Sirt1
inhibitor nicotinamide [7]. Taking into account that Sirt1 deacety-
lase was recently found to both suppress tumorigenesis and cancer
growth [8], isonicotinamide represents also a good choice for the
design of new antitumor drugs.
Among the compounds used in the cancer chemotherapy,
cisplatin is one of the most effective and potent antitumor drugs
[9]. Since the introduction of cisplatin in clinical treatments,
intensive efforts have been channeled towards the search for
cytotoxic compounds with more acceptable toxicity proﬁles but
retentive or even expansive activity. For a long time, the design of
new platinum antitumor drugs has mainly concentrated on direct
cisplatin analogues. More recently, structures that violate the
empirical structureeactivity relationships of platinum compounds,
such as multinuclear complexes, transplatin derivatives and
complexes based on other transition metals [10], are developed to
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discover “non-classical” drugs that can act in a different way from
cisplatin. Within this context, palladium(II) derivatives were
quickly selected due to their structural analogy with square planar
platinum(II) complexes.
Despite the fact that antitumor [11], antibacterial [12], anti-
trypanosomal [13], antifungal [14], antiherpetic [15], anti-inﬂam-
matory [16], antiamoebic [17] and anti-tubercular properties [18] of
palladium(II) compounds have been the subject of many reports,
studies on the biological activity of isonicotinamide-based Pd(II)
complexes remain unknown in literature.
For dichlorobis(isonicotinamide)palladium(II), [PdCl2(isn)2], an
additional site to be changed in this compound is occupied by
chlorido ligands which can be substituted by other anionic ligands.
The variation of the labile Cl ligand in metal complexes by pseu-
dohalides has been extensively used [18,19]. Such replacement is
expected to decrease the substitution rates for pseudohalides
compared with chlorido ligands which may contribute to stabili-
zation and biological activity in some of these Pd(II) species [20].
In the framework of our current research on the coordination
and biological chemistry of palladium(II) compounds [21], we
synthesized some palladium(II) compounds of the general
formulae [PdX2(isn)2] (X¼ Cl, N3, SCN, NCO; isn¼ isonicotinamide)
and evaluated their antimycobacterial and antitumor activities
against TB bacillus and murine tumor cell lines (LP07 and LM3),
respectively. The X-ray molecular structure of the compound trans-
[Pd(N3)2(isn)2] was also described in this work.
2. Chemistry
2.1. Materials
The reagents isonicotinamide (Aldrich), pseudohalide salts
(Riedel-de-Haën), PdCl2 (Degussa) and solvents (Merck) were
purchased commercially and used without further puriﬁcation.
Literature procedure was followed for the synthesis of
[PdCl2(MeCN)2] [22].
2.2. Physical measurements
Microanalysis (C, H, and N) was performed by the Central
Analítica, Universidade de São Paulo, on a PerkinElmer 2400 CHN
elemental analyzer. Melting points were determined on a Micro-
quimica MQAPF-302 apparatus. The infrared spectra were recorded
on an FT-IR Impact 400 model of the Nicolet Instrument Corpora-
tion spectrophotometer (KBr pellets, 4000e400 cm1). 1H and 13C
{1H} NMR spectrawere registered at 298 K, in DMSO-d6 solution, on
a Varian model Inova 500 spectrometer operating at 500 and
126 MHz, respectively.
2.3. Synthesis of the complexes
2.3.1. [PdCl2(isn)2] (1)
To a reddish-brown solution of [PdCl2(MeCN)2] (100 mg,
0.385 mmol) in CHCl3 (20 mL) under magnetic stirring, was added
a solution of isn (94.0 mg, 0.770 mmol) in CH3OH (5 mL). After
1 h, the yellow precipitated formed was separated by ﬁltration,
washed with CH3OH and dried in vacuo. Yield: 80%. Elemental anal.
Calcd for C12H12Cl2N4O2Pd: C, 34.19; H, 2.87; N, 13.29. Found: C,
34.05; H, 2.72; N, 13.03. IR data (KBr, cm1): nNeH 3412e3186(s);
nC]O 1705(s), dNH2 1614(m). 1H NMR (DMSO-d6, ppm): 8.89 [d,
3J ¼ 6.67 Hz, 4H, H2,6]; 8.38 [s, 2H, NH]; 7.90 [s, 2H, NH]; 7.86 [d,
3J ¼ 6.67 Hz, 4H, H3,5]. 13C{1H} NMR (DMSO-d6, ppm): 164.93 [C]
O]; 153.53 [C2,6]; 141.00 [C4]; 123.02 [C3,5]. Melting point (dec.):
>300 C.
2.3.2. [Pd(N3)2(isn)2] (2)
To a solution of [PdCl2(MeCN)2] (100 mg, 0.385 mmol) in CHCl3
(20 mL), was added isn (94.0 mg, 0.770 mmol) in CH3OH (5 mL).
Subsequently, 2 mL of H2O/CH3OH (1:1) containing NaN3 (50.1 mg,
0.770mmol) was added in the mixture that was kept under stirring
for 1 h. The dark-yellow suspension was ﬁltered off and the solid
was washed with deionized water and CH3OH, and dried in vacuo.
Yield: 85%. Elemental anal. Calcd for C12H12N10O2Pd: C, 33.16; H,
2.78; N, 32.22. Found: C, 33.17; H, 2.74; N, 31.99. IR data (KBr, cm1):
nNeH 3406e3207(m); nasN3 2008(s); nC]O 1670(s), dNH2 1610(s).
1H NMR (DMSO-d6, ppm): 8.89 [d, 3J ¼ 6.67 Hz, 4H, H2,6]; 8.43 [s,
2H, NH]; 7.97 [d, 3J ¼ 6.67 Hz, 4H, H3,5]; 7.77 [s, 2H, NH]. 13C{1H}
NMR (DMSO-d6, ppm): 164.77 [C]O]; 152.03 [C2,6]; 144.06 [C4];
123.91 [C3,5]. Melting point (dec.): >220 C.
2.3.3. [Pd(SCN)2(isn)2] (3)
This complex was prepared similarly to 2 with the exception
that NaSCN was used (62.4 mg, 0.770 mmol). The suspension was
ﬁltered off and the orange solid was washed with deionized water
and CH3OH, and dried in vacuo. Yield: 90%. Elemental anal. Calcd
for C14H12N6O2S2Pd: C, 36.02; H, 2.59; N, 18.00. Found: C, 35.89; H,
2.40; N, 17.91. IR data (KBr, cm1): nNeH 3369e3205(s); nasSCN
2118(s); nC]O 1674(s), d(NH2) 1626(s). Melting point (dec.):
>300 C.
2.3.4. [Pd(NCO)2(isn)2] (4)
Complex 4 was synthesized similarly to 2, employing KNCO
(62.5 mg, 0.770 mmol) instead of NaN3. After 1 h of magnetic
stirring, a light-yellow solid was isolated from the reaction media
by ﬁltration, washed with deionized water and CH3OH, and dried in
vacuo. Yield: 90%. Elemental anal. Calcd for C14H12N6O4Pd: C, 38.68;
H, 2.78; N, 19.33. Found: C, 38.26; H, 2.59; N, 19.68. IR data (KBr,
cm1): nNeH 3381e3186(s); nasNCO 2258(s); nC]O 1707(s), d(NH2)
1612(m). 1H NMR (DMSO-d6, ppm): 8.88 [d, 3J ¼ 6.67 Hz, 4H, H2,6];
8.37 [s, 2H, NH]; 7.89 [s, 2H, NH]; 7.86 [d, 3J ¼ 6.67 Hz, 4H, H3,5]. 13C
{1H} NMR (DMSO-d6, ppm): 164.95 [C]O]; 153.14 [C2,6]; 144.23
[C4]; 123.30 [C3,5]. Melting point (dec.): >288 C.
2.4. Crystal structure determination of complex 2
Single crystals suitable for X-ray analysis were obtained by
recrystallization fromDMSO. The crystal was mounted on an Enraf-
Nonius Kappa-CCD difractometer with graphite monochromated
Mo Ka (l¼ 0.71073A) radiation. The ﬁnal unit cell parameters were
based on all reﬂections. Data collections were made using the
COLLECT program [23]; integration and scaling of the reﬂections
were performed with the HKL Denzo-Scalepack system of
programs [24]. Absorption corrections were carried out numeri-
cally using the Gaussian method [25]. The structure was solved by
direct methods with SHELXS-97 [26]. Themodel was reﬁned by full-
matrix least squares on F2 bymeans of SHELXL-97 [26]. All hydrogen
atoms were stereochemically positioned and reﬁned with the
ridging model. Data collection and experimental details are
summarized in Table 1.
Fig. 1. Structural representation of INH (on the left), isn (center) and pza (on the right).
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CCDC 694418 contains the supplementary crystallographic data
for the structure reported in this paper. Copies of the data can be
obtained free of charge via http://www.ccdc.cam.ac.uk/products/
csd/request/, or from the Cambridge Crystallographic Data Centre,
12 Union Road, Cambridge CB2 1EZ, UK; fax: þ44 1223 336 033;
e-mail: deposit@ccdc.cam.ac.uk.
3. Pharmacology
3.1. Cell culture and MTT assay
LM3 and LP07 cell lines were generously supplied by Prof. Elisa
Bal De Kier Joffé from Cell Biology Department, Research Area,
Instituto de Oncología ‘Angel H. Roffo’, Universidad de Buenos
Aires, Buenos Aires, Argentina. LM3 and LP07 cells weremaintained
in MEM (Sigma) supplemented with 10% heat-inactivated FBS,
2 mmol L1 L-glutamine, and 80 mg mL1 gentamicin, deﬁned as
complete medium, in plastic ﬂasks (Corning) at 37 C in a humidi-
ﬁed 5% CO2 atmosphere [27]. Passages weremade by trypsinization
of conﬂuent monolayers (0.25% trypsin and 0.02% EDTA in
Ca2þeMg2þ free PBS). Cell number was counted by the Trypan blue
dye exclusion method.
Test solutions of the compounds (1000 mmol L1) were freshly
prepared by dissolving the substance in 50 mL of DMSO completed
with 4950 mL of culturemedium. Afterwards, the tested compounds
were diluted in culture medium to reach the ﬁnal concentrations
ranging from 500 to 50 mmol L1. The DMSO solvent in the
concentrations used in test did not reveal any cytotoxic activity.
For the cytotoxicity evaluation (MTT assay), 200.0 mL samples of
LM3 and LP07 cells (5  104 cell mL1, adjusted in MEM), were
added to each well of a 96-well tissue culture plate (Corning) and
then preincubated in the absence of compounds for 24 h to allow
adaptation of cells prior to the addition of the test agents. Then,
supernatants were removed and 200.0 mL of the compounds in
concentrations ranging from 2 to 140 mmol L1 or 200.0 mL of MEM-
Complete as cell control of viability was added to each well. The
effects of the compounds under the cells were determined 24 h
after culture incubation. Then, supernatants were removed and
100.0 mL of solution of [3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide] (MTT) was added in each well containing
the samples [28]. MTT assay was performed and the plates were
incubated for 3 h. Then, absorbances were measured and the
cytotoxic midpoint value, the concentration of chemical agent
needed to reduce the spectrophotometric absorbance to 50%, was
determined by linear regression analysis with 95% of conﬁdence
limits. The IC50 was deﬁned as the medium of two independent
experiments through the equation of graphic line obtained
(Microcal Origin 5.0). Each compound in a given concentration
was tested in triplicates in each experiment.
3.2. Antimycobacterial activity assay
Antimycobacterial activities of each tested compound were
determined in triplicate in sterile 96-well ﬂat bottomed
microplates (Falcon 3072; Becton Dickinson, Lincoln Park, NJ, USA)
and Middlebrook 7H9 Broth (Difco) supplemented with oleic
acidealbuminedextroseecatalase (OADC) enrichment (BBL/Becton
Dickinson, Sparks, MD, USA). The tested compound concentrations
ranged from 0.15 to 250 mg mL1. The microplate Alamar Blue assay
[29] (MABA) was used to measure the minimal inhibitory concen-
tration (MIC) for the tested compounds (minimum concentration
necessary to inhibit 90% growth of Mycobacterium tuberculosis
H37Rv ATCC 27294). Fluorescence measurements were taken on
a SPECTRAﬂuor Plus microﬂuorimeter (Tecan) in bottom reading
mode, with excitation at 530 nm and emission at 590 nm.
4. Results and discussion
The precursor [PdCl2(MeCN)2] reacts with isonicotinamide (isn)
to afford [PdCl2(isn)2] (1). Compounds [Pd(N3)2(isn)2] (2), [Pd
(SCN)2(isn)2] (3) and [Pd(NCO)2(isn)2] (4) are readily obtained by
metathesis of the chlorido ligands in 1 by azide, thiocyanate and
cyanate salts, respectively. A general scheme which represents the
strategy employed for the synthesis of the complexes is illustrated
in Fig. 2.
4.1. IR and NMR spectroscopy
Isonicotinamide molecule possesses three potential donor
sites: (i) pyridine ring nitrogen; (ii) amino nitrogen; (iii) carbonyl
oxygen. Among spectroscopic techniques employed to infer the
bonding mode of the isonicotinamide [30,31], IR spectroscopy is
the most widely used method. The vibrational modes associated
Table 1
Crystallographic data and reﬁnement details for trans-[Pd(N3)2(isn)2] (2).
Empirical formula C12H12N10O2Pd
Formula weight 434.72
Temperature (K) 296(2)
Crystal system Monoclinic
Space group C2/c
a (A) 8.3829(4)
b (A) 9.8649(5)
c (A) 18.9459(8)
b () 92.763(3)
Volume (A3) 1564.94(13)
Z 4
Density calculated (g/cm3) 1.845
Absorption coefﬁcient (mm1) 1.218
F(000) 864
Crystal size (mm3) 0.182  0.150  0.115
q range for data collection () 3.19 to 26.00
Index ranges 10  h  10
12  k  10
22  l  23
Reﬂections collected 5046
Independent reﬂections (Rint) 1514 (0.0284)
Data/restraints/parameters 1514/0/116
Goodness-of-ﬁt on F2 1.071
Final R indices [I > 2s(I)] R1 ¼ 0.0369, wR2 ¼ 0.0924
R indices (all data) R1 ¼ 0.0480, wR2 ¼ 0.1014
Largest diff. peak and hole/e A3 0.876 and 0.706
Extinction coefﬁcient 0.0032(7)
Completeness to q ¼ 26.00 99.1%
Fig. 2. General scheme for the synthesis of the complexes.
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with amide group and pyridine ring give important information
about the coordination fashion of the isn ligand. It is well estab-
lished that, if coordination takes place through carboxyl oxygen, it
is expected a shift to lower frequencies of the nC]O band when
compared to that one of the free ligand (1666 cm1) [30e32]. On
the other hand, when the amino nitrogen atom is involved in
coordination, nNH2 and dNH2 absorptions shift to lower frequen-
cies [30,31]. The coordination of the pyridine-type nitrogen shifts
to higher frequencies some vibrational modes of the heterocyclic
ring (e.g. ring breathing) due to coupling with MeNpy bond
vibrations [33].
The IR spectra of 1e4 exhibited the characteristic bands of
amide group at 3412e3186 cm1 (nNH2), ca. 1689 cm1 (nC]O) and
w1615 cm1 (dNH2). These absorptions remain either unchanged
or undergo a slight high frequency shift when compared to those of
the free ligand [30,31], indicating that amide group does not take
part in coordination. The pyridine ring breathing mode of coordi-
nated isn in 1e4 at w1062 cm1 is shifted to higher frequencies
when compared to that observed for free ligand (993 cm1)
[30e32], which is attributed to the coordination of isonicotinamide
through pyridine-type nitrogen atom. In addition, the existence of
terminally coordinated pseudohalides is evidenced in the IR spectra
of 2, 3 and 4 by the presence of one single and strong band at
2008 cm1 (2), 2118 cm1 (3) and 2258 cm1 (4), assigned to nasN3
[34], nasSCN [35] and nasNCO [36] modes, respectively.
NMR studies in DMSO-d6 also support the attachment of iso-
nicotinamide via pyridine-type nitrogen atom. The 1H NMR spec-
trum of isonicotinamide (isn) consists of two dublets at 8.71 ppm
(3J ¼ 6.0 Hz) and 7.76 ppm (3J ¼ 6.0 Hz), associated to the two
adjacent protons present on either side of the pyridine ring,
whereas the two broad signals at 8.23 and 7.70 ppm are attributed
to the amide protons. In the 1H NMR spectra of freshly prepared
samples of 1, 2 and 4, there is a downﬁeld shift of the ring proton
signals (8.71e8.89 ppm and 7.76 to ca. 7.92 ppm) whereas the two
amide hydrogens do not undergo signiﬁcant shifts. On the other
hand, compound 3 displays a very complex NMR spectrum with
multiple broad signals over the spectral range 9.3e7.6 ppm, sug-
gesting that 3 is ﬂuxional at room temperature.
Besides the signals of the pyridine ring, the 13C{1H} NMR spectra
of 1e4 showed the carbonyl resonance of amide moiety at ca.
165 ppm which is very close to that observed for the free ligand
(166.39 ppm), indicating that carbonyl group does not take part in
coordination.
4.2. X-ray structure of trans-[Pd(N3)2(isn)2] (2)
The MERCURY representation of trans-[Pd(N3)2(isn)2] (2) and
a view of the 2D network structure formed by hydrogen bonding
are shown in Fig. 3, which was generated by the Mercury 1.4.2
software [37]. Selected bond distances and angles are given in
Table 2.
The palladium atom is located on the crystallographic inversion
center giving rise to a slightly distorted square planar environment
with four nitrogen atoms (two from the azido ligands and two from
the isonicotinamide ligands) in trans conﬁguration. The angle
values are 92.25(15) for N4ePdeN1 and 87.75(15) for N4ePdeN1*.
The PdeNisn bond length of 2.016(3)A is comparable to that found
in trans-[PdCl2(nicotinamide)2] (2.017 A) and cis-[Pd(bu2bipy)
(isn)2]þ2 (average 2.03 A) [38], whereas the PdeNazide bond
distance (2.104 A) is longer than those found in trans-[Pd
(N3)2(1-phenyl-3-methylpyrazole)2] (2.031 A) [39] and trans-[Pd
(N3)2(quinoline)2] (2.038 A) [40]. Another structural parameter of
interest is the quasi-linearity and the asymmetry observed for the
NeN distances in the azido group coordinated to palladium atom
(N1eN2eN3 ¼ 174.59(6), N1eN2 ¼ 1.130(7) A and N2eN3 ¼ 1.180
(7) A). It is worth mentioning that the existence of strong inter-
molecular NeH/O hydrogen bonds are responsible for the self-
assembly of the monomers into a two-dimensional supramolecular
array, Fig. 3(b).
Fig. 3. (a) Mercury representation of trans-[Pd(N3)2(isn)2] (2) showing the labeling of
the atoms; (b) View of 2D network structure formed by hydrogen bonding in 2 along
a axis.
Table 2
Selected bond lengths (A) and angles () for the complex trans-[Pd(N3)2(isn)2] (2).
PdeN4 2.016(3) N4ePdeN4a 180.0(3)
PdeN1 2.104(4) N4ePdeN1 92.25(15)
OeC6 1.21(1) N4ePdeN1a 87.75(15)
N5eC6 1.32(1) N1ePdeN1a 180.0(3)
N1eN2 1.130(7) N1eN2eN3 174.59(6)
N2eN3 1.180(7) PdeN1eN2 115.3(4)
DeH/A D/A H/A DeH/A
NeH/O 2.885 2.038 167.98
CeH/N 3.560 2.685 157.15
a Symmetry transformations used to generate equivalent atoms: 1xþ3/2,yþ1/
2, z.
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4.3. Antimycobacterial activity
Isonicotinamide, [PdCl2(MeCN)2], complexes 1e4, and a selec-
tion of pseudohalide salts (NaN3, KNCO and NaNCS) were each
evaluated for their antiproliferative activities against M. tubercu-
losis. The minimum inhibitory concentration (MIC) values are
depicted in Table 3.
As shown in Table 3, isonicotinamide and [PdCl2(MeCN)2] were
essentially inactive against the pathogen. The coordination of the
metal produced compounds which were more active than
uncomplexed isonicotinamide and pseudohalide salts, with MIC
values ranging from 35.6 to 297 mmol L1. It was apparent that the
potency in the series was affected by the anionic ligand coordinated
to Pd(II). The replacement of two chlorido by two thiocyanato
(1 / 3) or two cyanato ligands (1 / 4) did not result in any
increase in the anti-tubercular activity. On the other hand, the
azido-complex trans-[Pd(N3)2(isn)2] (2) was ca. 8 fold more active
than compounds 1, 3 and 4. In order to understand possible reasons
for the different activity of 2, the pseudohalides salts NaN3, KNCO
and NaNCS were tested in the same experimental condition. The
results showed that NaN3 inhibits the growth of M. tuberculosis at
39 mg mL1 and is approximately threefold more toxic than NaNCS
and KNCO salts. Such ﬁnding may indicate that coordination of
azide ligand exerts an extra effect on the anti-tubercular activity of
the isonicotinamide-based Pd(II) complex. Nevertheless, further
studies on this class of compounds are required in order to ratio-
nalize the obtained MIC values in terms of structureeactivity
relationship as well as to understand the mechanism of action. It is
important to point out that complex 2 is also more effective against
M. tuberculosis than other palladium compounds of the type [Pd
(C2,N-dmba)(X)tu] (dmba ¼ N,N-dimethylbenzylamine; X ¼ Cl, Br;
tu ¼ thiourea) whose MIC values vary from 58 to 89 mmol L1 [18].
It is worth to emphasize that compounds 1e4 possess higher
inhibitory activity than pyrazinamide (MIC value of
406e812 mmol L1), used for tuberculosis treatment [41]. On the
other hand, none of the synthesized complexes was more active
than isoniazid (MIC 0.05 mmol L1), one of the ﬁrst-line anti-
tubercular drugs [29].
4.4. Antitumor activity
IC50 values (the concentration that inhibited in 50% the cellular
proliferation) on breast tumor cells (LM3) and lung tumor cells
(LP07) are presented in Table 4. For comparison purposes, the
cytotoxicity of cisplatin, a standard antitumor drug, was also eval-
uated under the same conditions.
Despite the fact that the free isonicotinamide is inactive against
the tested culture cell lines, its coordination on palladium(II) center
resulted in a signiﬁcant decrease of the IC50 values. However, none
of the synthesized complexes were more active than cisplatin.
5. Conclusions
The synthesis, structural and spectroscopic characterization as
well as the biological activity of palladium(II) compounds con-
taining isonicotinamide were described in this work. The mono-
dentate coordination mode of the isonicotinamide ligand via
pyridine-like nitrogen atom was clearly evidenced for all prepared
complexes. The complex trans-[Pd(N3)2(isn)2] (2) was the most
active palladium(II) compound against M. tuberculosis and
demonstrated to be more potent than pyrazinamide, a standard
drug used for tuberculosis treatment. Evaluation of the antitumor
activity indicated that all Pd(II) compounds were less active than
cisplatin towards breast tumor cells (LM3) and lung tumor cells
(LP07).
Further studies on the antitumor and antimycobacterial activi-
ties of palladium(II) and other metal-based derivatives are also
underway in our laboratories in order to gain more information
about the mechanism of action of these palladium(II) complexes
bearing isonicotinamide.
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